Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells

European Journal of Immunology

Volumn 36, Issue 3, 2006, Pages 681-689

  Nencioni, Alessio ^a   Garuti, Anna ^a   Schwarzenberg, Karin ^b   Cirmena, Gabriella ^a   Dal Bello, Giovanna ^a   Rocco, Ilaria ^a   Barbieri, Eleonora ^a   Brossart, Peter ^b   Patrone, Franco ^a   Ballestrero, Alberto ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Apoptosis; Cancer; Dendritic cells; Proteasome

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CASPASE; CYCLOHEXIMIDE; EPOXOMICIN; PROTEASOME INHIBITOR; PROTEIN BAX;

APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; MEMBRANE DAMAGE; MITOCHONDRIAL MEMBRANE; MONOCYTE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELLS, CULTURED; DENDRITIC CELLS; HUMANS; MITOCHONDRIA; MONOCYTES; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BIOSYNTHESIS; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 33644958956     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200535298     Document Type: Article

References (56)

1. Adams, J., The proteasome: A suitable antineoplastic target. Nat. Rev. Cancer 2004. 4: 349-360.
2. Adams, J., The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004. 5: 417-421.
3. Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V. et al., A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 2003. 48: 2609-2617.
4. Jagannath, S., Barlogie, B., Berenson, J., Siegel, D., Irwin, D., Richardson, P. G., Niesvizky, R. et al., A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br. J. Haematol. 2004. 127: 165-172.
5. Goy, A., Younes, A., McLaughlin, P., Pro, B., Romaguera, J. E., Hagemeister, F., Fayad, L. et al., Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 2005. 23: 667-675.
6. O'Connor, O. A., Wright, J., Moskowitz, C., Muzzy, J., MacGregor-Cortelli, B., Stubblefield, M., Straus, D. et al., Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J. Clin. Oncol. 2005. 23: 676-684.
7. Orlowski, R. Z., Voorhees, P. M., Garcia, R. A., Hall, M. D., Kudrik, F. J., Allred, T., Johri, A. R. et al., Phase I trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005. 105: 3058-3065.
8. Cortes, J., Thomas, D., Koller, C., Giles, F., Estey, E., Faderl, S., Garcia-Manero, G. et al., Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin. Cancer Res. 2004. 10: 3371-3376.
9. Papandreou, C. N., Daliani, D. D., Nix, D., Yang, H., Madden, T., Wang, X., Pien, C. S. et al., Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J. Clin. Oncol. 2004. 22: 2108-2121.
10. Kondagunta, G. V., Drucker, B., Schwartz, L., Bacik, J., Marion, S., Russo, P., Mazumdar, M. et al., Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J. Clin. Oncol. 2004. 22: 3720-3725.
11. Shah, M. H., Young, D., Kindler, H. L., Webb, I., Kleiber, B., Wright, J. and Grever, M., Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin. Cancer Res. 2004. 10: 6111-6118.
12. Blaney, S. M., Bernstein, M., Neville, K., Ginsberg, J., Kitchen, B., Horton, T., Berg, S. L. et al., Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: A Children's Oncology Group study (ADVL0015). J. Clin. Oncol. 2004. 22: 4752-4757.
13. Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C. et al., Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc. Natl. Acad. Sci. USA 2002. 99: 14374-14379.
14. Jana, N. R., Dikshit, P., Goswami, A. and Nukina, N., Inhibition of proteasomal function by curcumin induces apoptosis through mitochondrial pathway. J. Biol. Chem. 2004. 279: 11680-11685.
15. Ling, Y. H., Liebes, L., Zou, Y. and Perez-Soler, R., Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J. Biol. Chem. 2003. 278: 33714-33723.
16. Jana, N. R., Zemskov, E. A., Wang, G. H. and Nukina, N., Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal Huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum. Mol. Genet. 2001. 10: 1049-1059.
17. Nencioni, A., Hua, F., Dillon, C. P., Yokoo, R., Scheiermann, C., Cardone, M. H., Barbieri, E. et al., Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis. Blood 2005. 105: 3255-3262.
18. Lee, A. H., Iwakoshi, N. N., Anderson, K. C. and Glimcher, L. H., Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc. Natl. Acad. Sci. USA 2003. 100: 9946-9951.
19. Fribley, A., Zeng, Q. and Wang, C. Y., Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol. Cell. Biol. 2004. 24: 9695-9704.
20. Wu, J., On the role of proteasomes in cell biology and proteasome inhibition as a novel frontier in the development of immunosuppressants. Am. J. Transplant. 2002. 2: 904-912.
21. Luo, H., Wu, Y., Qi, S., Wan, X., Chen, H. and Wu, J., A proteasome inhibitor effectively prevents mouse heart allograft rejection. Transplantation 2001. 72: 196-202.
22. Sun, K., Welniak, L. A., Panoskaltsis-Mortari, A., O'Shaughnessy, M. J., Liu, H., Barao, I., Riordan, W. et al., Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc. Natl. Acad. Sci. USA 2004. 101: 8120-8125.
23. Vanderlugt, C. L., Rahbe, S. M., Elliott, P. J., Dal Canto, M. C. and Miller, S. D., Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519. J. Autoimmun. 2000. 14: 205-211.
24. Zollner, T. M., Podda, M., Pien, C., Elliott, P. J., Kaufmann, R. and Boehncke, W. H., Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model. J. Clin. Invest. 2002. 109: 671-679.
25. Kita, H., Ansari, A. A., He, X. S., Lian, Z. X., Van de Water, J., Coppel, R. L., Luketic, V. et al., Proteasome is required for class I-restricted presentation by Fcγ receptor-mediated endocytosis in primary biliary cirrhosis. J. Autoimmun. 2003. 21: 175-182.
26. Song, P. H., Xie, H. Y., Zheng, S. S. and Wu, J., The inhibitory role of lactacystin and beta-lactacystin on T-cell activation and proliferation. Acta Biochim. Biophys. Sin. (Shanghai) 2004. 36: 123-127.
27. Derouet, M., Thomas, L., Cross, A., Moots, R. J. and Edwards, S. W., Granulocyte macrophage colony-stimulating factor signaling and proteasome inhibition delay neutrophil apoptosis by increasing the stability of Mcl-1. J. Biol. Chem. 2004. 279: 26915-26921.
28. Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y. J., Pulendran, B. et al., Immunobiology of dendritic cells. Annu. Rev. Immunol. 2000. 18: 767-811.
29. Reis e Sousa, C., Activation of dendritic cells: Translating innate into adaptive immunity. Curr. Opin. Immunol. 2004. 16: 21-25.
30. Sallusto, F. and Lanzavecchia, A., Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J. Exp. Med. 1994. 179: 1109-1118.
31. Kisselev, A. F. and Goldberg, A. L., Proteasome inhibitors: From research tools to drug candidates. Chem. Biol. 2001. 8: 739-758.
32. Hengartner, M. O., The biochemistry of apoptosis. Nature 2000. 407: 770-776.
33. Zheng, B., Georgakis, G. V., Li, Y., Bharti, A., McConkey, D., Aggarwal, B. B. and Younes, A., Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-κB mutations or activation of the CD30, CD40, and RANK receptors. Clin. Cancer Res. 2004. 10: 3207-3215.
34. Chen, W. J. and Lin, J. K., Induction of G1 arrest and apoptosis in human Jurkat T cells by pentagalloylglucose through inhibiting proteasome activity and elevating p27Kip1, p21Cip1/WAF1, and Bax proteins. J. Biol. Chem. 2004. 279: 13496-13505.
35. Nakaso, K., Yoshimoto, Y., Yano, H., Takeshima, T. and Nakashima, K., p53-mediated mitochondrial dysfunction by proteasome inhibition in dopaminergic SH-SY5Y cells. Neurosci. Lett. 2004. 354: 213-216.
36. Pei, X. Y., Dai, Y. and Grant, S., The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. Leukemia 2003. 17: 2036-2045.
37. Chang, Y. C., Lee, Y. S., Tejima, T., Tanaka, K., Omura, S., Heintz, N. H., Mitsui, Y. et al., mdm2 and box, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway. Cell Growth. Differ. 1998. 9: 79-84.
38. Danial, N. N. and Korsmeyer, S. J., Cell death: critical control points. Cell 2004. 116: 205-219.
39. Suzuki, M., Youle, R. J. and Tjandra, N., Structure of Bax: Coregulation of dimer formation and intracellular localization. Cell 2000. 103: 645-654.
40. Yu, J., Tiwari, S., Steiner, P. and Zhang, L., Differential apoptotic response to the proteasome inhibitor bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer cells. Cancer. Biol. Ther. 2003. 2: 694-699.
41. Vogelstein, B., Lane, D. and Levine, A. J., Surfing the p53 network. Nature 2000. 408: 307-310.
42. Johnson, T. R., Stone, K., Nikrad, M., Yeh, T., Zong, W. X., Thompson, C. B., Nesterov, A. et al., The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xl overexpressing cells. Oncogene 2003. 22: 4953-4963.
43. Wagenknecht, B., Hermisson, M., Groscurth, P., Liston, P., Krammer, P. H. and Weller, M., Proteasome inhibitor-induced apoptosis of glioma cells involves the processing of multiple caspases and cytochrome c release. J. Neurochem. 2000. 75: 2288-2297.
44. Kitagawa, H., Tani, E., Ikemoto, H., Ozaki, I., Nakano, A. and Omura, S., Proteasome inhibitors induce mitochondria-independent apoptosis in human glioma cells. FEBS Lett. 1999. 443: 181-186.
45. Stanciu, M. and DeFranco, D. B., Prolonged nuclear retention of activated extracellular signal-regulated protein kinase promotes cell death generated by oxidative toxicity or proteasome inhibition in a neuronal cell line. J. Biol. Chem. 2002. 277: 4010-4017.
46. Ludewig, B., Junt, T., Hengartner, H. and Zinkernagel, R. M., Dendritic cells in autoimmune diseases. Curr. Opin. Immunol. 2001. 13: 657-662.
47. Hackstein, H. and Thomson, A. W., Dendritic cells: Emerging pharmacological targets of immunosuppressive drugs. Nat. Rev. Immunol. 2004. 4: 24-34.
48. Morelli, A. E. and Thomson, A. W., Dendritic cells: Regulators of alloimmunity and opportunities for tolerance induction. Immunol. Rev. 2003. 196: 125-146.
49. Giver, C. R., Li, J. M., Hossain, M. S., Lonial, S. and Waller, E. K., Reconstructing immunity after allogeneic transplantation. Immunol. Res. 2004. 29: 269-282.
50. Nencioni, A., Grunebach, F., Zobywlaski, A., Denzlinger, C., Brugger, W. and Brossart, P., Dendritic cell immunogenicity is regulated by peroxisome proliferator-activated receptor γ. J. Immunol. 2002. 169: 1228-1235.
51. Nencioni, A., Lauber, K., Grunebach, F., Brugger, W., Denzlinger, C., Wesselborg, S. and Brossart, P., Cyclopentenone prostaglandins induce caspase activation and apoptosis in dendritic cells by a PPAR-γ-independent mechanism: Regulation by inflammatory and T cell-derived stimuli. Exp. Hematol. 2002. 30: 1020-1028.
52. Brossart, P., Zobywalski, A., Grunebach, F., Behnke, L., Stuhler, G., Reichardt, V. L., Kanz, L. et al., Tumor necrosis factor alpha and CD40 ligand antagonize the inhibitory effects of interleukin 10 on T-cell stimulatory capacity of dendritic cells. Cancer Res. 2000. 60: 4485-4492.
53. Ballestrero, A., Nencioni, A., Boy, D., Rocco, I., Garuti, A., Mela, G.S., Van Parijs, L. et al., Tumor necrosis factor-related apoptosis-inducing ligand cooperates with anticancer drugs to overcome chemoresistance in antiapoptotic Bcl-2 family members expressing Jurkat cells. Clin. Cancer Res. 2004. 10: 1463-1470.
54. Ballestrero, A., Coviello, D. A., Garuti, A., Nencioni, A., Fama, A., Rocco, I., Bertorelli, R. et al., Reverse-transcriptase polymerase chain reaction of the maspin gene in the detection of bone marrow breast carcinoma cell contamination. Cancer 2001. 92: 2030-2035.
55. Shintaku, S., Ohdan, H., Yamamoto, H., Miyata, Y., Hayashi, A., Ito, H., Fukuda, Y. et al., Expression of bcl-2 homologue mRNAs in rat liver allograft: Rejection-induced cell apoptosis is associated with upregulation of bax and bcl-xs expression. Transpl. Int. 1998. 11 Suppl 1: S284-S288.
56. Spallarossa, P., Garibaldi, S., Altieri, P., Fabbi, P., Manca, V., Nasti, S., Rossettin, P. et al., Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J. Mol. Cell. Cardiol. 2004. 37: 837-846.